Clinical Trial Update: Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing tofacitinib versus methotrexate in patients with rheumatoid arthritis and interstitial lung disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder) | Phase 4 | Status: TERMINATED